SIRPA and neoplasm: In this context, a promising recombinant SIRPα molecule fused to the human IgG1 Fc domain (TTI-621) minimally bound to human erythrocytes, thus displaying reduced toxicity in pre-clinical models, and yet efficiently bound to tumor cells [206].